Healthcare
Evolent Health, Inc.(EVH)
Live Price
Offline$4.49
-3.85% today
1Y Change
-58.08%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $450.00M
- Revenue Growth
- -26.6%
- EPS Growth
- -525.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Evolent Health, Inc. (EVH) is a Healthcare stock with a market cap of $450.00M and listed on NYSE. The stock last traded around $4.49 and down 58.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -26.6%, EPS growth of -525.9%, a dividend yield of 0.0%. What stands out right now is revenue -26.6%, EPS -525.9%, free cash flow +177.6% with operating margin -0.6% and ROIC -0.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EVH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-26.6% vs +7.6% peer median
Operating Margin
Below sector median
-0.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -26.6% and EPS is at -525.9%, with operating margin around -0.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.4% | -6.3% | +17.1% |
2026 Feb 24, 2026 | +33.3% | +22.7% | +37.1% | -12.1% |
2025 Nov 6, 2025 | -50.0% | -17.3% | -30.7% | -34.3% |
Benchmark Edge
EVH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EVH
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EVH Max Drawdown
-81.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EVH and SPY.
Company Overview
Evolent Health, Inc.
New York Stock Exchange
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
- Leadership
- Seth Barrie Blackley
- IPO Date
- Jun 5, 2015
- Employees
- 4.5k
- Street Address
- 800 North Glebe Road
- Mailing
- Arlington, VA, 22203
- Region
- Arlington, VA, US
- Reporting Currency
- USD
- Investor Line
- 571 389 6000
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.2
- Price/Book
- 1.1
Growth
- Revenue
- -26.6%
- EPS
- -525.9%
- Free Cash Flow
- +177.6%
Profitability
- Gross Margin
- 15.1%
- Operating Margin
- -0.6%
- Net Margin
- -28.5%
- ROE
- -69.2%
- ROIC
- -0.8%
Balance Sheet
- Debt/Equity
- 2.38
- Current Ratio
- 1.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.